New drugs that predominantly target amino acids in the HIV-1 RT pocket that cannot mutate without seriously compromising RT function will be developed. Subunitdimerisation of HIV-1 RT p66/p51 will be explored as a new tool for drug development. Also a recently discovered new micro target on RT will be investigated for development of drugs that lack cross-resistance to Notes and Norris . We will develop modalities to control endogenous dent pool ratios to attenuate the resistance spectrum of Nets and Knurls . Finally, we will develop a small animal model based on cats that are infectable by an FIV clone in which the RT has been made sensitive to the HIV-1-specific Norris, to fill the existing preclinical gap between HIV resistance research in cell culture and in the clinical setting.
Funding SchemeCSC - Cost-sharing contracts
171 77 Stockholm
28801 Alcala De Henares
3584 CL Utrecht